Catalent, Inc. (NYSE:CTLT) Given Consensus Rating of “Hold” by Analysts

Catalent, Inc. (NYSE:CTLT) has been given a consensus recommendation of “Hold” by the seven brokerages that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $63.40.

CTLT has been the subject of a number of recent research reports. Robert W. Baird reissued a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com initiated coverage on shares of Catalent in a report on Friday, December 27th. They set a “hold” rating for the company. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th.

Catalent Price Performance

CTLT stock opened at $63.48 on Friday. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50. The company has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The business’s 50 day moving average price is $61.18 and its two-hundred day moving average price is $59.78. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, analysts forecast that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CTLT. Millennium Management LLC grew its position in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares during the period. Bank of Montreal Can grew its holdings in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after acquiring an additional 1,169,044 shares during the period. National Bank of Canada FI increased its position in Catalent by 300.0% during the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after acquiring an additional 1,095,578 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after acquiring an additional 863,624 shares during the period. Finally, ING Groep NV boosted its position in Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after purchasing an additional 699,851 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.